Edition:
United Kingdom

BIOLASE Inc (BIOL.OQ)

BIOL.OQ on NASDAQ Stock Exchange Capital Market

1.86USD
17 May 2019
Change (% chg)

-- (--)
Prev Close
$1.86
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
9,270
52-wk High
$2.86
52-wk Low
$0.91

Summary

Name Age Since Current Position

Jonathan Lord

63 2017 Chairman of the Board of directors

Todd Norbe

51 2018 President, Chief Executive Officer, Director

John Beaver

57 2018 Chief Financial Officer, Executive Vice President

Brendan O'Connell

39 2015 Vice President - Finance and Corporate Controller

James Surek

2017 Vice President - Sales, Americas

Michael Roux

2016 Vice President of Marketing

Matthew Wilson

2016 Vice President of Human Resources

Samuel Low

2016 Vice President - Dental and Clinical Affairs, Chief Dental Officer

Terence Kelly

54 2014 Director

Richard Lanman

62 2017 Director

Jess Roper

2018 Director

Garrett Sato

57 2018 Director

Elaine Wagner

2018 Director

Todd Kehrli

IR Contact Officer

Michael Polyviou

IR Contact Officer

Biographies

Name Description

Jonathan Lord

Dr. Jonathan (Jack) T. Lord, MD is a Chairman of board of directors of the company since 2017. Dr. Lord also serves as Chairman of the Compensation Committee. Dr. Lord is a board-certified forensic pathologist and Fellow of the College of American Pathologists. From March 2012 to January 2013, Dr. Lord was the Chief Operating Officer of the University of Miami Leonard M. Miller School of Medicine and the Uhealth-University of Miami Health System, a healthcare network in south Florida. From August 2011 to March 2012, Dr. Lord served as the Chief Innovation Officer at the University of Miami, Florida. From April 2009 to January 2010, Dr. Lord served as President and Chief Executive Officer of Navigenics, Inc., a privately held healthcare company. Prior to this role, he served as a senior executive in a variety of healthcare organizations including the Anne Arundel Medical Center and SunHealth and served as the Chief Operating Officer of the American Hospital Association. Dr. Lord is also the former Chief Innovation Officer and Senior Vice President of Humana Inc. He began his medical career in the U.S. Navy, serving for 11 years in a number of leadership roles in the Navy. Dr. Lord holds BSC degree in Chemistry and MD from University of Miami.

Todd Norbe

Mr. Todd Norbe is President, Chief Executive Officer, Director of the Company since 2018. He was most recently President, North America of KaVo Kerr, a subsidiary of the Danaher Corporation that provides dental instruments, imaging solutions, dental treatment units and related consumables worldwide, where he held executive leadership positions from 2006 to 2018. Previously, Mr. Norbe served as Vice President and General Manager of Metrex Medical – Sybron Dental Specialties, continuing in that role after it was acquired by Danaher in 2006. Mr. Norbe has a Master of Business Administration in Management from Fairleigh Dickinson University and a Bachelor of Science degree in Marketing from Bloomsburg University.

John Beaver

Mr. John R. Beaver is Chief Financial Officer, Executive Vice President of the Company since 2018. Mr. Beaver served as the Chief Financial Officer of Silicor Materials, Inc., a global leader in the production of solar silicon, from 2009 to 2013 and 2015 to 2017. Mr. Beaver also served on the Board of Directors of Silicor Materials, Inc. from 2013 to 2015. From 2013 to 2015, Mr. Beaver was Chief Financial Officer for Modumetal, Inc., a nano-laminated alloy coatings company focused on oil and gas applications. Prior to 2009, Mr. Beaver was Senior Vice President – Finance and Chief Financial Officer at Sterling Chemicals, a mid-sized public commodity chemical manufacturer. Mr. Beaver holds a Bachelor of Business Administration in Accounting from the University of Texas at Austin and is a Certified Public Accountant.

Brendan O'Connell

Mr. Brendan O'Connell is a appointed as Vice President - Finance and Corporate Controller in January 2015. Mr. O’Connell began his career with Biolase as our Assistant Controller in May 2007 and was promoted to serve as our Corporate Controller effective February 2009. Mr. O’Connell earned a Bachelor of Science in Accounting and an M.B.A. from University of California, Riverside.

James Surek

Mr. James D. Surek is a Vice president - Sales, Americas of the company since 2017.

Michael Roux

Mr. Michael Roux is Vice President of Marketing of the company. He has significant leadership experience in marketing and product management and comes to BIOLASE with a wide range of medical device and multinational business expertise with leading publicly-owned companies. Most recently, Mr. Roux served for three years as Vice President of Product Management with Patient Safety Technologies, which was acquired by Stryker in 2014. Prior to that, Mr. Roux spent four years as Global Product Director for the Respiratory Care franchise of Hill-Rom, and 19 years at 3M Company where he held positions of increasing responsibility within product engineering, six-sigma, global product marketing leadership and business development groups. Mr. Roux holds a Bachelor of Science Degree in Industrial Engineering from the University of Minnesota, and a Masters of Business Administration in Marketing from the University of St. Thomas.

Matthew Wilson

Mr. Matthew Wilson is Vice President of Human Resources of the company. He brings over 15 years of experience in Human Resources Management in diverse industries, including dental medical device, commercial real estate and aerospace. Most recently, Mr. Wilson served for nearly eight years as Human Resources Director for the Zimmer Biomet, Inc. (previously Zimmer, Inc.) dental business. Prior to that role, Mr. Wilson spent over three years at CBRE Group, Inc. as Human Resources Director and Senior Organization Development Consultant. Mr. Wilson began his career in Human Resources in Raytheon Company's two-year Human Resources Leadership Development Program, followed by an additional three years as Principal Human Resources Generalist for the company's Integrated Airborne Systems organization. Mr. Wilson holds a Masters of Business Administration in International Management from Thunderbird School of Global Management and a Bachelor of Arts in Marketing from the University of Utah.

Samuel Low

Dr. Samuel B. Low, D.D.S., M.S., M.Ed., serves as Vice President - Dental and Clinical Affairs, Chief Dental Officer of the Company. He was Independent Director of the company. Dr. Low is Professor Emeritus, University of Florida, College of Dentistry and Associate faculty member of the Pankey Institute, with 30 years of private practice experience in periodontics, lasers and implant placement. He is also a Diplomate of the American Board of Periodontology and past President of the American Academy of Periodontology. Dr. Low provides dentists and dental hygienists the tools for successfully managing the periodontal patient in general and periodontal practices. He was selected "Dentist of the Year" by the Florida Dental Association, Distinguished Alumnus by the University of Texas Dental School, and the Gordon Christensen Lecturer Recognition Award. He is a Past President of the Florida Dental Association and past ADA Trustee. Dr. Low received his Doctor of Dental Surgery (D.D.S.) and Master of Science (M.S.) degrees from the University of Texas at Houston. He also completed his residency in Periodontics at the University of Texas at Houston, and received a Masters of Education from the University of Florida.

Terence Kelly

Dr. Terence A. Kelly, Ph.D., is appointed as Director of Biolase Inc., effective June 16, 2014. He has over 20 years of experience as a scientist and executive in the pharmaceutical industry starting as a medicinal chemist in 1990. Dr. Kelly is currently the President and Chief Executive Officer of CoMentis, Inc., a venture-backed private biotech company focused on neurodegenerative diseases, and a founder of Kelly Pharma Research Consulting, LLC. From 1990 to 2009, Dr. Kelly served in various scientific and executive positions at Boehringer Ingelheim, where after a successful early career developing LFA-1 antagonists, he led its US-based medicinal chemistry department, which included 145 scientists in the high throughput screening, computational chemistry, structural biology, combinatorial chemistry and medicinal chemistry groups. Dr. Kelly holds a B.S. degree in Chemistry at Rensselaer Polytechnic Institute (1982) and a Ph.D. degree in Chemistry at the University of Texas at Austin (1988). He completed postdoctoral work in natural products synthesis at Yale University (1988-1990) and holds an MBA from New York University, Stern School of Business (1998). Dr. Kelly is the co-author of over 25 scientific publications and serves on the College of Natural Sciences Advisory Council for the University of Texas.

Richard Lanman

Dr. Richard (Rick) B. Lanman M.D., is a Director of the Company since 2017. From July 2008 until September 2014 Dr. Lanman was with Veracyte, Inc., where he drove the validation and clinical utility studies required to commercialize genomic diagnostics in thyroid and lung neoplasia that facilitate improved diagnosis utilizing small, minimally-invasive biopsies. Veracyte went public in 2013. He also previously served as Chief Medical Officer for two cardiovascular biodiagnostic companies, diaDexus and Atherotech, and prior to that, Dr. Lanman was the medical director and senior vice president of San Jose Medical Group and a Chief of Quality at Kaiser Permanente. Dr. Lanman completed his internship and residency at the University of California San Francisco, after receiving his medical degree from Northwestern University and a Bachelor of Science in chemistry from Stanford University, where he graduated Phi Beta Kappa.

Jess Roper

Mr. Jess Roper is a Director of the company since 2018. He was most recently Senior Vice President and Chief Financial Officer of Dexcom, Inc., where he held executive leadership positions from 2005 to 2017. Dexcom is a San Diego-based developer and marketer of continuous glucose monitoring systems for ambulatory use by patients and by healthcare providers in hospitals. Mr. Roper previously held financial management positions with two other publicly traded companies and one venture-funded company. Earlier in his career, Mr. Roper was an auditor with PricewaterhouseCoopers, and a bank and information systems examiner with the Office of the Comptroller of the Currency. Mr. Roper has a Master of Science in Corporate Accountancy and a Bachelor of Science in Business Administration in Finance from San Diego State University, and is a Certified Public Accountant.

Garrett Sato

Mr. Garrett Sato is a Director of the Company since 2018. He is a resident of Newport Beach, CA, has more than 30 years of experience as a successful consultant and senior executive with companies in the dental industry and has served as a senior advisor and executive partner with private equity and investment banking firms. Most recently, from December 2013 to February 2016, he was Chairman and Chief Executive Officer of California-based Danville Materials LLC, a developer and manufacturer of dental clinic materials. As an industry executive operating partner with the private equity firm of Inverness Graham Investments, he led Denville through a period of revenue growth of approximately 35%, increased EBITDA by nearly 240%, improved operating margins and implemented a three-year strategic plan. Zest Dental Solutions, Inc., acquired Danville Materials in February 2016. Previously, from June 2011 through December 2013, Mr. Sato served as a consultant and advisor to several businesses, including New Zealand-based Triodent Corporation, where he served as Executive Director; Santa Barbara, CA-based Isolite Corporation; Kyoto, Japan-based Shofu Corporation; Canada-based Clinicians Research Dental Inc.; and Japan-based Mani Corporation. From October 2009 to June 2011, Mr. Sato was Executive Vice President of Culver City, CA-based Discus Dental, a Philips Company. At Discus Dental, Mr. Sato helped plan and executed a successful strategic turnaround that resulted in improved revenue and profit gains. Mr. Sato has a Bachelor of Science degree in marketing from California State University, Long Beach.

Elaine Wagner

Dr. Elaine C. Wagner is a Director of the Company since 2018. Elaine Wagner is a retired United States Navy Rear Admiral with 33 of service. She was most recently the Director of Readiness and Health at the Navy Bureau of Medicine and Surgery in Falls Church, Virginia, where she served from 2014 to 2017. From 2011 to 2014, she served as the commander of Navy Medicine East and Naval Medical Center Portsmouth, and previously served as Commanding Officer of the Navy Expeditionary Medical Center in Kuwait, the Naval Health Clinic New England, and the Naval Hospital Beaufort, South Carolina, following tours of duty in Washington, D.C., the Philippines, Japan, and San Diego. Dr. Wagner has a Bachelor of Arts from Butler University and a Doctor of Dental Surgery from Indiana School of Dentistry.

Todd Kehrli

Michael Polyviou